Epizyme Inc. (EPZM) Given Consensus Rating of “Buy” by Brokerages
Epizyme Inc. (NASDAQ:EPZM) has been given a consensus rating of “Buy” by the ten research firms that are currently covering the firm. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $24.43.
A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday, August 10th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Tuesday, August 9th. JMP Securities reiterated a “buy” rating and issued a $28.00 price target on shares of Epizyme in a research note on Thursday, June 23rd. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $39.00 price target on shares of Epizyme in a research note on Tuesday, June 21st.
Epizyme (NASDAQ:EPZM) traded down 3.39% on Tuesday, reaching $9.40. The company’s stock had a trading volume of 112,215 shares. The stock’s market cap is $544.79 million. The firm’s 50-day moving average price is $8.66 and its 200-day moving average price is $10.15. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.29.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/epizyme-inc-epzm-given-consensus-rating-of-buy-by-brokerages.html
Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative return on equity of 43.05% and a negative net margin of 5,174.49%. On average, equities analysts expect that Epizyme will post ($2.20) earnings per share for the current year.
In related news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the transaction, the insider now directly owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 25.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Woodstock Corp raised its position in shares of Epizyme by 37.3% in the third quarter. Woodstock Corp now owns 37,800 shares of the biopharmaceutical company’s stock valued at $372,000 after buying an additional 10,266 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Epizyme by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 127,302 shares of the biopharmaceutical company’s stock valued at $1,304,000 after buying an additional 2,250 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Epizyme during the second quarter valued at about $518,000. Palo Alto Investors LLC raised its position in shares of Epizyme by 2.1% in the second quarter. Palo Alto Investors LLC now owns 2,711,381 shares of the biopharmaceutical company’s stock valued at $27,765,000 after buying an additional 55,902 shares in the last quarter. Finally, Iguana Healthcare Management LLC bought a new position in shares of Epizyme during the second quarter valued at about $2,048,000. 80.79% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.